F. Couch

发表

Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study.

M. King, M. Skolnick, D. Easton, 1996, American journal of human genetics.

Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2

F. Couch, B. Bonanni, T. Rebbeck, 2011, British Journal of Cancer.

PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2

S. Cross, P. Fasching, J. Olson, 2012, British Journal of Cancer.

Plus : development and validation of a prognostic model for early breast cancer that includes HER 2

T. Nielsen, M. García-Closas, G. Giles, 2012 .

A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening.

M. Skolnick, F. Couch, S. Ingles, 1995, JAMA.

Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families

D. B. Berman, F. Couch, T. Rebbeck, 1996, Nature Medicine.

Rapid progression of prostate cancer in men with a BRCA2 mutation

P Ghadirian, F. Couch, D. Horsman, 2008, British Journal of Cancer.

Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia

C. Doriguzzi, U. Linz, K. Keating, 1993, Nature Genetics.

Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants

J. Hopper, A. Spurdle, J. Visvader, 2005, Journal of Medical Genetics.

Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)

G Rennert, N Weerasooriya, K Offit, 2009, British Journal of Cancer.

PALB 2 , CHEK 2 and ATM rare variants and cancer risk : data from COGS

R. Winqvist, K. Pylkäs, M. Tischkowitz, 2016 .